...
glyc-img

GlycoMimetics Inc, Common Stock

GLYC

NAQ

$0.242

+$0.03

(13.86%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$13.96M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
394.72K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.84
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.14 L
$3.53 H
$0.242

About GlycoMimetics Inc, Common Stock

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGLYCSectorS&P500
1-Week Return-7.12%-0.33%-1.49%
1-Month Return-24.62%-4.57%-0.37%
3-Month Return31.61%-9.96%3.89%
6-Month Return-18.79%-5.67%9.34%
1-Year Return-91.41%2.53%25.19%
3-Year Return-85.66%-1.43%24.7%
5-Year Return-96.14%34.73%85.39%
10-Year Return-97.23%102.14%187.19%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue9.00M10.16M1.16M74.92K10.00K[{"date":"2019-12-31","value":88.56,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":11.41,"profit":true},{"date":"2022-12-31","value":0.74,"profit":true},{"date":"2023-12-31","value":0.1,"profit":true}]
Cost of Revenue899.30K-1.01M1.03M153.30K[{"date":"2019-12-31","value":87.13,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":98.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":14.85,"profit":true}]
Gross Profit(899.30K)10.16M1.16M74.92K10.00K[{"date":"2019-12-31","value":-8.85,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":11.41,"profit":true},{"date":"2022-12-31","value":0.74,"profit":true},{"date":"2023-12-31","value":0.1,"profit":true}]
Gross Margin(9.99%)100.00%100.00%100.00%100.00%[{"date":"2019-12-31","value":-9.99,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses61.39M61.67M64.61M47.48M39.29M[{"date":"2019-12-31","value":95.02,"profit":true},{"date":"2020-12-31","value":95.46,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.49,"profit":true},{"date":"2023-12-31","value":60.81,"profit":true}]
Operating Income(61.39M)(51.51M)(63.45M)(47.40M)(39.28M)[{"date":"2019-12-31","value":-6138900000,"profit":false},{"date":"2020-12-31","value":-5150900000,"profit":false},{"date":"2021-12-31","value":-6344700000,"profit":false},{"date":"2022-12-31","value":-4740300000,"profit":false},{"date":"2023-12-31","value":-3927529300,"profit":false}]
Total Non-Operating Income/Expense6.99M964.00K39.77K1.43M4.62M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":13.78,"profit":true},{"date":"2021-12-31","value":0.57,"profit":true},{"date":"2022-12-31","value":20.44,"profit":true},{"date":"2023-12-31","value":66.02,"profit":true}]
Pre-Tax Income(57.89M)(51.03M)(63.43M)(46.69M)(36.90M)[{"date":"2019-12-31","value":-5789200000,"profit":false},{"date":"2020-12-31","value":-5102700000,"profit":false},{"date":"2021-12-31","value":-6342700000,"profit":false},{"date":"2022-12-31","value":-4668800000,"profit":false},{"date":"2023-12-31","value":-3689942000,"profit":false}]
Income Taxes(3.78M)(752.75K)(284.60K)46.64M(637.00)[{"date":"2019-12-31","value":-8.1,"profit":false},{"date":"2020-12-31","value":-1.61,"profit":false},{"date":"2021-12-31","value":-0.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(54.12M)(50.27M)(63.14M)(93.33M)(36.90M)[{"date":"2019-12-31","value":-5411576600,"profit":false},{"date":"2020-12-31","value":-5027424600,"profit":false},{"date":"2021-12-31","value":-6314240000,"profit":false},{"date":"2022-12-31","value":-9332859668,"profit":false},{"date":"2023-12-31","value":-3689878300,"profit":false}]
Income From Continuous Operations(57.89M)(51.03M)(63.43M)(46.69M)(38.06M)[{"date":"2019-12-31","value":-5789191100,"profit":false},{"date":"2020-12-31","value":-5102690300,"profit":false},{"date":"2021-12-31","value":-6342743700,"profit":false},{"date":"2022-12-31","value":-4668835900,"profit":false},{"date":"2023-12-31","value":-3806408100,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(54.12M)(50.27M)(63.14M)(93.33M)(36.90M)[{"date":"2019-12-31","value":-5411576600,"profit":false},{"date":"2020-12-31","value":-5027424600,"profit":false},{"date":"2021-12-31","value":-6314240000,"profit":false},{"date":"2022-12-31","value":-9332859668,"profit":false},{"date":"2023-12-31","value":-3689942000,"profit":false}]
EPS (Diluted)(1.35)(1.11)(1.23)(0.88)(0.58)[{"date":"2019-12-31","value":-135,"profit":false},{"date":"2020-12-31","value":-111,"profit":false},{"date":"2021-12-31","value":-123,"profit":false},{"date":"2022-12-31","value":-88,"profit":false},{"date":"2023-12-31","value":-58,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GLYC
Cash Ratio 3.33
Current Ratio 3.62

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GLYC
ROA (LTM) -59.25%
ROE (LTM) -104.49%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GLYC
Debt Ratio Lower is generally better. Negative is bad. 0.28
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.72

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GLYC
Trailing PE NM
Forward PE NM
P/S (TTM) 1396.08
P/B 1.32
Price/FCF NM
EV/R 94.04
EV/Ebitda NM
PEG NM

FAQs

What is GlycoMimetics Inc share price today?

GlycoMimetics Inc (GLYC) share price today is $0.242

Can Indians buy GlycoMimetics Inc shares?

Yes, Indians can buy shares of GlycoMimetics Inc (GLYC) on Vested. To buy GlycoMimetics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GLYC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of GlycoMimetics Inc be purchased?

Yes, you can purchase fractional shares of GlycoMimetics Inc (GLYC) via the Vested app. You can start investing in GlycoMimetics Inc (GLYC) with a minimum investment of $1.

How to invest in GlycoMimetics Inc shares from India?

You can invest in shares of GlycoMimetics Inc (GLYC) via Vested in three simple steps:

  • Click on Sign Up or Invest in GLYC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in GlycoMimetics Inc shares
What is GlycoMimetics Inc 52-week high and low stock price?

The 52-week high price of GlycoMimetics Inc (GLYC) is $3.53. The 52-week low price of GlycoMimetics Inc (GLYC) is $0.14.

What is GlycoMimetics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of GlycoMimetics Inc (GLYC) is

What is GlycoMimetics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of GlycoMimetics Inc (GLYC) is 1.32

What is GlycoMimetics Inc dividend yield?

The dividend yield of GlycoMimetics Inc (GLYC) is 0.00%

What is the Market Cap of GlycoMimetics Inc?

The market capitalization of GlycoMimetics Inc (GLYC) is $13.96M

What is GlycoMimetics Inc’s stock symbol?

The stock symbol (or ticker) of GlycoMimetics Inc is GLYC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top